• Director Alvino Mark sells 8,000 shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) but retains a significant stake, indicating continued confidence in the company's future.
• FDA approval of ZEVASKYN™ marks Abeona's transition to a commercial-stage company, highlighting a significant milestone in its development of therapies for rare diseases.
• Financial stability is bolstered by a $155 million sales agreement for a priority review voucher, covering over two years of operating expenses and setting the stage for future growth and profitability.

Abeona Therapeutics Inc. (NASDAQ:ABEO) is a biotechnology company focused on developing cell and gene therapies for rare diseases. Recently, Alvino Mark, a director at Abeona, sold 8,000 shares of the company's common stock at $5.68 each. Despite this sale, Mark still holds 92,435 shares, indicating continued confidence in the company's future.

Abeona's recent Q1 2025 earnings call, held on May 15, 2025, featured key executives and analysts discussing the company's financial performance and strategic direction. The call highlighted the FDA approval of ZEVASKYN™, a groundbreaking gene therapy for RDEB patients. This approval marks Abeona's transition to a commercial-stage company, as noted by CEO Vish Seshadri.

The company has also entered into a significant sales agreement for a priority review voucher valued at $155 million. CFO Joe Vazzano emphasized that the proceeds from this sale will cover over two years of operating expenses, excluding potential sales from ZEVASKYN. This financial stability positions Abeona well for future growth and profitability, expected by early 2026.

ABEO's stock is currently priced at $6.10, reflecting a 5.35% increase. The stock has fluctuated between $5.62 and $6.12 today, with a market capitalization of approximately $297.68 million. The trading volume on the NASDAQ exchange is 1,374,904 shares, indicating strong investor interest in the company's recent developments.